Mirjam G.A. oude Egbrink

TL;DR: A review of state-of-the-art knowledge on the composition and functions of the endothelial glycocalyx can be found in this article, where the contribution of the glyocalyx to diabetes, ischemia/reperfusion, and atherosclerosis is also reviewed.

TL;DR: A combination therapy in which angiostatic agents are used as well is put forward as a novel strategy to treat cancer.

TL;DR: The regulation of leukocyte-vessel wall interactions by the presence of a tumor may have an impact on the effectiveness of clinical immunotherapeutic treatment protocols, because immune effector cells may not be able to enter tumor tissue.

TL;DR: The new angiostatic designer peptide anginex was most potent at overcoming EC anergy; the enhanced leukocyte‐vessel interactions led to an increase in the numbers of tumor infiltrating leukocytes, and the current results suggest that immunotherapy strategies can be improved by combination with anti‐angiogenesis.

TL;DR: In vivo metabolized nebivolol increases vascular NO production, and this phenomenon involves endothelial beta(2)-adrenergic receptor ligation, with a subsequent rise in endothelial free [Ca(2+)](i) and endothelial NO synthase-dependent NO production.